From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q4 2021 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”转变为“在买家自己的采购、报销、处方集、规格、采购、网络、目录或计划系统中获得批准、指定、列入、合格、注册、报销或预先授权”的状态,从而使得未来业务中相当一部分可以无需每次单独销售即可到达,并且管理层是否传达了这种准入状态是新的,以至于其解锁的大部分量仍在前方。 在记录中,管理层提到了与沃尔玛的合作(在3800家门店推出)、与国药、H&H、Ro、Designs for Health等合作伙伴的关系。但关键问题是:这些是否属于“将公司纳入常规购买路径”的准入状态?例如,被列入批准供应商名单、处方集、报销目录等。记录中并没有明确提到公司被纳入任何此类系统。管理层谈论的是合作伙伴关系和分销协议,但这些都是普通的销售关系,每次订单仍需单独说服。此外,管理层提到“我们正在最终确定与国药的商业计划和供应协议”,这表明尚未完成。对于Designs for Health,是“提供专门配方的产品”,但也是普通的分销关系。没有提到任何具体的准入状态,如被列入处方集或供应商名单。 管理层还提到“我们与沃尔玛的推出”,但这是零售分销,不是准入状态。没有提到“批准”、“指定”、“列入”等词汇。因此,答案应为NO。 此外,管理层没有明确说这种状态是新的,并且大部分量还在前方。他们提到了一些合作伙伴的贡献,但都是常规的销售增长。 因此,答案是否定的。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.